LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.99 -1.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.93

Max

4.09

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+72.84% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.7M 289M
Iepriekšējā atvēršanas cena	5.47
Iepriekšējā slēgšanas cena	3.99

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. maijs 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026. g. 29. maijs 23:06 UTC

Iegādes, apvienošanās, pārņemšana

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026. g. 29. maijs 20:53 UTC

Peļņas

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026. g. 29. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 20:33 UTC

Tirgus saruna

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026. g. 29. maijs 20:11 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 19:47 UTC

Peļņas

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026. g. 29. maijs 19:36 UTC

Tirgus saruna

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026. g. 29. maijs 19:22 UTC

Tirgus saruna

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026. g. 29. maijs 19:05 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026. g. 29. maijs 18:19 UTC

Tirgus saruna

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026. g. 29. maijs 18:12 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026. g. 29. maijs 18:11 UTC

Tirgus saruna

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026. g. 29. maijs 18:10 UTC

Tirgus saruna

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026. g. 29. maijs 17:55 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 17:55 UTC

Tirgus saruna

NEAR Protocol Nearly Doubles in May -- Market Talk

2026. g. 29. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026. g. 29. maijs 17:00 UTC

Peļņas

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 29. maijs 16:02 UTC

Tirgus saruna

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026. g. 29. maijs 15:40 UTC

Tirgus saruna

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026. g. 29. maijs 15:20 UTC

Tirgus saruna

Canada's Economy Not Looking All That Bright -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

72.84% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 72.84%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.